PRRT2 and Alzheimer disease: The modulation of PKC activity, particularly the PKCδ and PKCε isoforms, is one potential effective way to trigger α-secretase processing of APP, producing non-toxic sAPPα instead of toxic Aβ, preventing senile plaque formation and AD-associated cognitive deficits (Yi et al., 2012).